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visceral metastasis were excluded from the study. All the patients 
were treated in two phases to a total dose of 5940cGy. Phase I CTV 
(treated to a dose of 45Gy in 25 fractions) was generated by 
expanding the GTV primary cranio-caudally by 4cm and laterally to 
include electively, the corresponding level mediastinal nodes. Phase II 
CTV was generated by expanding the GTV by 2cm craniocaudally and 
1cm radially. Bilateral supraclavicular regions were electively 
included for supracarinal lesions. ITV was generated by expanding the 
CTV by 0.5cm which was then expanded by 0.5cm to yield PTV. IG-RA 
plans consisted of 2 conformal arcs with a high priority to reduce lung 
V20, mean lung dose and heart dose. The set-up was verified by daily 
KV imaging as well as thrice weekly CBCT with oral barium. 
Chemotherapy consisted of 4-6 cycles of weekly cisplatin 40mg/m2. 
Results: The median age of patients was 53 yrs (43-72).The median 
length of involvement of esophagus was 6cm with 80% of the lesions in 
the upper and middle third. 37/41(90%) patients completed planned 
chemotherapy with atleast 4 cycles of cisplatin and 40/41 patients 
completed full dose of radiotherapy. 4/41 (10%) patients required 
tube feeding, 2/41 (5%)patients required hospital admission for 
supportive care but none of the patients had grade IV hematological 
toxicity during treatment. Endoscopy at 8 weeks post treatment was 
performed in 38/41 patients of whom 20 (53%) had CR,16 (42%) had PR 
and 2 (5%) had stable disease locally. With a median follow up of 15 
(6-20) months, 18/41(44%) patients are alive at last follow-up of which 
13 (32%) are disease free with no dysphagia, the 1 and 2 year overall 
survival are 70% and 42% respectively and median survival of 13.5 
months. 3/18 (16%)alive patients have post radiotherapy stricture 
requiring occasional dilatations. Unfortunately none of the patients 
underwent salvage surgery because of various medical and social 
reasons. After analyzing KV image datasets, the modal corrections 
applied for bone matching was 0.1cm (vertical),0.2cm (lateral and 
0.2cm longitudinal. The analysis of CBCT data sets showed that the 
ITV and PTV margins of 0.5cm each were found to be adequate with 
current imaging protocol. 
Conclusions: Image guided volumetric modulated arc therapy to a 
dose of 60Gy with concurrent weekly cisplatin is a feasible treatment 
option for locally advanced inoperable squamous cell carcinoma of 
thoracic esophagus with low acute and late toxicity and with 
promising early clinical outcomes. The ITV and PTV margins of 0.5cm 
were found to be adequate only with image guidance.  
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Purpose/Objective: VEGFR, EGFR, Cox-2 and p53 stimulates key 
processes involved in tumor growth, progression and proliferation, and 
are important targets for cancer therapeutics. Ki-67 is a marker of 
tumor activity.The prognostic and predictive value of these novel 
biomolecular markers expression in association with proliferation in 
selecting targeted agents is currently unknown.The purpose of this 
study was to measure co-expression of EGFR, VEGFR, Cox-2, p53 and 
Ki67 proteins in pre-treatment tumor biopsies of rectal cancer 
patients treated with neoadjuvant treatment and to correlate 
expression with clinical outcome. 
Materials and Methods: EGFR,VEGFR, Cox-2, p53 and Ki67 co-
expression was measured using immunohistochemistry quantitative 
image analysis. Ki67% activity (positive ≥90%) was quantified within 
EGFR, VEGFR, Cox-2 and p53 tumor in high versus low expression. Cox 
proportional hazards models were used to explore associations 
between the tumor markers and disease-free survival (DFS). 
Results: 38 pre-treatment tumors were analyzed. Patients median 
follow-up was 69.3 months (range,4.5-92). Onunivariate analysis, high 
Ki67% activity in VEGFR (HR 4.06 [1.14, 14.43], p =0.03), Cox-2 (HR 
3.89 [1.12, 13.45], p = 0.03); and p53 (HR 4.15 [1.07, 16.07], p Z 0.04) 
high expression tumors was associated with worse DFS. On 
multivariate analysis, only high Ki67% activity in VEGFR high 
expression tumors remained statistically significant forDFS (HR 4.07 
[1.14, 14.3], p = 0.04). 
Conclusions: High Ki67% activity in VEGFR high expression tumors are 
associated with worse DFS in patients with rectal cancer treated with 
induction CT followed by pelvic CRTand surgery. Determination of the 
optimal diagnostic cut-off level for this novel biomarker association 
should be explored. Evaluation within a clinical trial will be required 
to determine whether patients could benefit from an VEGFR targeted 
therapeutic agent. 
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Purpose/Objective: This study investigated the utility of deformable 
image registration in accurately assessing the pattern of local relapse 
with respect to the high dose treatment volume in patients with 
oesophageal cancer following chemoradiation. 
Materials and Methods: Data was collected for 15 patients treated 
between 2009 and 2010. Seven of these patients (46.7%) relapsed; two 
patients (13.3%) had infield recurrence and five (33.3%) experienced 
distant recurrence. All patients were treated with chemoradiation (as 
per the NCRI UK SCOPE trial protocol but not all treated witihin the 
trial) and received conformal radiotherapy of 50Gy in 25 fractions to 
the PTV. This PTV was derived from a CTV based on a CT scan with 
information from un-registered PET-CT and endoscopic ultrasound. 
Retrospectively, deformable image registration was performed 
(Mirada RTx, Mirada Medical, Oxford, UK) between the original 
planning CT and the PET-CT images. Tumour volumes were contoured 
on the PET-CT images and projected onto the original planning CT. In 
addition, for local relapse patients, deformable image registration 
was carried out between the planning CT and the relapse CT images. 
(Figure 1) The site of relapse was contoured and projected onto the 
planning CT. This enabled comparison of the site of relapse relative to 
the planning CT and PET-CT volumes and the dose received by each 
volume to evaluate tumour coverage. Dosimetric analysis was 
undertaken. (Table 1)  
Results: Deformable registration (not rigid body) was necessary to 
accurately transfer relapse CT derived contours to the planning CT as 
the patients typically had different curvature of the spine and 
oesophagus in the PET-CT and diagnostic relapse CT compared to 
planning CT. Of the two local relapses, one was within the PET-CT 
volume whilst the other was in the high dose penumbra (small cell 
oesophageal cancer). This patient died of distant metastatic disease. 
 
Table 1: D95% (i.e. dose (Gy) to 95% of volume) results for relapse 
patients 
Contour 
Patient 
1 
Patient 
2 
Patient 
3 
Patient 
4 Patient 5 Patient 6 Patient 7 
GTV 49.99 50.24 49.54 50.24 49.65 50.30 48.86 
CTV or 
CTVa/CTVb48.53 n-a 49.37 49.24 49.58/49.24 48.83/48.99 47.19/47.47
PTV 48.13 49.84 n-a 48.70 48.30 47.03 42.94 
PET 
Volume 50.12 49.99 49.80 50.21 49.93 50.43 48.57 
Relapse 
Tumour 
Volume 
n-a 8.36 n-a n-a n-a n-a 47.45 
Figure 1: Deformable co-registered image of relapse CT and planning 
CT scan  
 
Black = Original Planning Target Volume 
White = Relapse region 
 
Conclusions: Deformable image registration is a valuable tool that 
allows relapse CT data to be compared accurately to the original 
planning CT and therefore determine if current target definition is 
adequate. Investigation of a larger cohort is required to confirm these 
observations by including this this procedure in the analysis of future 
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clinical trials. If significant local relapse is prevalent in the high dose 
region then dose escalation could be considered. Using this technique, 
PET-CT imaging during treatment may identify those patients more 
likely to relapse locally allowing earlier salvage therapy. 
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Purpose/Objective: We previously showed that a moderately 
hypofractionated RT with Tomotherapy (41.4 Gy in 18 fractions) 
concomitant to oxaliplatin and 5-FU is effective and well tolerated 
and that rectal volume variations, assessed by daily MVCT performed 
by tomotherapy, are smaller and more stable during the second half 
of the treatment so that a margin of 0.5 cm around the rectum is 
sufficient to include more than 90% of its volumetric variations. These 
data, and the hypothesis that the residual tumor still visible on 
CT/MRI after 10 radiotherapy fractions and two cycles of 
chemotherapy, could represent a more radio-chemo resistant 
component of disease, suggest the adoption of adaptive tomotherapy 
approach in rectal cancer. 
The aim of the study was to investigate the feasibility of preoperative 
adaptive radio-chemotherapy by delivering a concomitant boost to the 
residual tumour during the last 6 fractions of treatment. 
 Materials and Methods: Twenty-five patients with T3/T4N0 or N+ 
rectal cancer were enrolled. Concomitant chemotherapy consisted of 
Oxaliplatin 100mg/m2 on days -14, 0, +14, and 5-FU 200mg/m2/day 
from day -14 to the end of radiotherapy (day 0 is the start of 
Radiotherapy). Radiotherapy consisted in the delivery of 41.4 Gy in 18 
fractions (2.3 Gy/fraction) with Tomotherapy to the tumor and 
regional lymph-nodes (PTV) defined on CT/MRI imaging. After 9 
fractions CT and MR were repeated for the planning of the adaptive 
phase: PTVadapt was generated by adding a 5mm margin to the residual 
tumour. In the last 6 fractions, a boost of 3.0 Gy/fr (in total 45.6 Gy 
in 18 fractions) was delivered to PTVadapt while concomitantly 
delivering 2.3 Gy/fr to PTV outside PTVadapt. 
Results: Three patients experienced G3 gastrointestinal toxicity; 
toxicity occurred before the adaptive phase in 2/3 patients. A full 
dose of RT, Oxaliplatin, and 5-FU was delivered in 96%, 96%, and 88% 
of patients, respectively. Two patients with clinical complete 
response (cCR) refused surgery and were still cCR at 17 and 29 
months. For the remaining 23 resected patients, 15/23 (65%) showed 
TRG3 response and 7/23 had pathological complete response (pCR, 
30%); 8 (35%) and 12 (52%) TRG3 patients had ≤5% and 10% residual 
viable cells respectively. When considering cCR+pCR+TRG3 with viable 
cells<10%, the rate of major response was 84% (21/25). 
Conclusions: Adaptive boost strategy is feasible with an acceptable 
G3 GI toxicity rate and a very encouraging tumour response rate. The 
results suggest that there should still be room for further dose 
escalation with the aim of increasing pCR and/or cCR rates. 
   
PO-0697   
Salvage oesophagectomy after definitive chemo-radiotherapy: 
current evidence 
Z.G. Zhang1, Q.N. Zhang1, X.H. Wang1 
1Gansu Cancer Hospital, Department of Radiation Oncology, Lanzhou, 
China  
 
Purpose/Objective: To access the efficacy and safety of salvage 
oesophagectomy after failed definitive chemoradiotherapy for 
advanced esophageal cancer. 
Materials and Methods: A systematically literature searches of 
Medline, Embase, ISI Web of Knowledge, Cochrane Library and China 
Biological Medicine Database were undertaken in October 
2012.Clinical studies about salvage oesophagectomy were included 
without language or study design restriction. The studies of a sample 
less than 10 were excluded for inexperience of salvage 
oesophagectomy. The primary outcomes were survival and 
complication. The quality of including studies was accessed using the 
Oxford 2011 Levels of Evidence. Hazard ratios (HRs) for overall 
survival (OS) were combined with an inverse variance method based 
on logarithmic conversion. Odds ratios (ORs) and mean difference 
(MD) with 95% confidence intervals (CIs) were used to analyze 
dichotomous and continuous variables, respectively. All statistical 
analyses were undertaken in Review Manager 5.1 and random effect 
model was used. 
Results: Ten studies (8 cohort and 2 uncontrolled studies) were 
included, the quality of included studies was poor. Overall 307 
patients performed salvage oesophagectomy. The 1-, 3-and 5-years OS 
rates in salvage oesophagectomy group based on 265 patients were 
66%, 41%, and 32%, respectively. Pooled analyses based on 2 studies 
demonstrated that salvage oesophagectomy was associated with 
longer survival than non-surgery treatment after local failure of 
definitive chemoradiotherapy, the HR of OS was 0.39(95%CI:0.24-0.65; 
p=0.0003). but when compared with planned surgery, meta-analyses 
based on 6 studies suggested that salvage oesophagectomy was 
associated with worse survival (HR=1.66,95% CI:1.11-2.47; p=0.01), 
and higher in-hospital mortality (OR=2.99,95%CI:1.67-5.35;p=0.0002), 
longer hospital stay (MD=8.35,95%CI:1.86- 14.85; p=0.01),more 
anastomotic leak (OR=2.56,95%CI:1.38-4.74;p=0.003), more wound 
infection(OR=1.98,95%CI:1.10-3.59; p=0.02), more pulmonary event 
(OR=1.86,95%CI:1.32-2.63; p=0.004).The primary prognostic factors 
for favorable survival after salvage oesophagectomy were complete 
resection (HR=3.76; p<0.00001) based on 5 studies and early tumor 
stage (HR=7.5; p=0.08)based on 3 studies. One including study 
reported that the outcome in patients with remnant tumors was 
poorer than in those with recurrence (p<0.01). 
Conclusions: With the rare clinical evidence, salvage oesophagectomy 
was considered as a hopeful treatment after local failure of definitive 
CRT. But with more complication and higher surgical difficulties than 
planned surgery, patients should be chosen more carefully. 
Meanwhile, higher surgical technique was required on surgeon. 
Because of the small sample and the low quality of current studies, 
more clinical studies are still needed. 
   
PO-0698   
Radiotherapy±chemotherapy in the treatment of anal canal cancer: 
A single-institute long-term experience. 
M. Maddalo1, F. Barbera1, B. De Bari1, P. Vitali1, L. Lestrade1, L. 
Donadoni1, L. Triggiani1, R. Cavagnini1, S. Pandini1, S.M. Magrini1 
1Spedali Civili di Brescia - University of Brescia, Radiation Oncology 
Department - Istituto del Radio, Brescia, Italy  
 
Purpose/Objective: To retrospectively evaluate efficacy and toxicity 
of radio- ± chemotherapy (RT ± CT) in the management of anal canal 
carcinoma. 
Materials and Methods: Data of patients (pts) with an histological 
diagnosis of anal canal carcinoma were reviewed. Local Control (LC) 
and the acute and late toxicity rates were the primary endpoints of 
the analysis.Secondary endpoints are listed in Table 1. 
Results: From 02/1992 to 10/2010, 100 pts (M/F ratio: 17/83)were 
treated with curative RT with (58 pts) or without (42 pts) 
chemotherapy. Median age was 70 years (range: 33-91). According to 
the 2002 UICC TMN classification,13, 51, 14 and 22 tumors were 
staged as Stage I, II, IIIa and IIIb,respectively. 29% of the pts were N1-
3 and 14 pts presented positive inguinal nodes. Following the clinical 
conditions, RT was delivered on the initial tumor site with (68%) or 
without (32%) pelvic irradiation (upper field border: L5-S1) with a 
standard fractionation (1.8/2Gy). Median dose on the pelvis was 45Gy 
(range: 36-54), while a median total dose of 60Gy (range: 38-70)was 
delivered on the anal canal. Bilateral inguinal irradiation was 
delivered in 70 pts,with a curative (13%, one groin N+ patient having 
received lymphadenectomy before RT) or a prophylactic (57%) goal, at 
a median dose of 36Gy (range:36-66.6Gy). Median LC time was not 
reached, while 5- and10-years LC rates were 73% and 67%, 
respectively. Overall acute and late G3-4 toxicity rates were 32% 
(particularly skin G3 toxicity, 30/32 pts) and 18% (particularly rectal 
G3 toxicity, 7/18 pts), respectively, with 22 pts having undergo a 
colostomy, but with only 2 pts having received it to treat a G4 anal 
toxicity. All these pts received colostomy in the first 3 years after the 
end of the RT±CT. Sphincter function was evaluated in the remaining 
78 pts (with the Womack scale) and classified as a total continence or 
incontinence to gazes (score A-B) in 73 pts and a sincontinence to 
liquid stools (score C) in 5 pts or total incontinence (score D) in 2 pts. 
Table 1 shows results of the univariate and multivariate analysis on 
the primary and secondary endpoints. 
 
